Pre-clinical studies suggest a fundamental role for JAK signalling in the pathogenesis of enthesitis [14], and upadacitinib has been shown to inhibit the phosphorylation of the signalling molecule STAT1 in entheseal cells, leading to reduced production of the inflammatory cytokines TNF and IL-17 [15]. This evidence concerns the gene IL17A and enthesitis.